🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/12/2017 25,00 25,00 24,68 24,77 +1,72% 1,28% 16.977
06/12/2017 25,20 25,20 24,35 24,35 -3,91% 3,37% 17.266
05/12/2017 25,76 26,00 25,05 25,34 -2,54% 3,69% 18.551
04/12/2017 26,40 26,40 25,50 26,00 -0,12% 3,41% 20.384
01/12/2017 26,80 27,48 25,00 26,03 +4,12% 9,25% 73.652
30/11/2017 22,95 25,44 22,95 25,00 +9,89% 10,85% 92.433
29/11/2017 22,14 23,00 21,93 22,75 +2,76% 4,83% 34.344
28/11/2017 21,81 22,15 21,47 22,14 +1,56% 3,12% 17.391
27/11/2017 21,43 21,85 21,31 21,80 +2,11% 2,52% 36.611
24/11/2017 21,30 21,40 20,75 21,35 +0,71% 3,05% 20.216
23/11/2017 21,00 21,40 20,96 21,20 +1,44% 2,10% 28.444
22/11/2017 20,95 20,97 20,69 20,90 +1,21% 1,34% 136.269
21/11/2017 20,50 20,75 20,50 20,65 +0,73% 1,22% 48.849
20/11/2017 20,50 20,64 20,40 20,50 +0,29% 1,17% 3.241
17/11/2017 20,70 20,70 20,29 20,44 -0,10% 1,98% 6.496
16/11/2017 20,44 20,95 20,32 20,46 +0,89% 3,08% 11.016
15/11/2017 20,40 20,45 20,01 20,28 +0,05% 2,16% 10.196
14/11/2017 20,05 20,30 20,00 20,27 +1,35% 1,50% 10.731
13/11/2017 20,16 20,50 19,75 20,00 -0,70% 3,72% 29.227
10/11/2017 19,93 20,14 19,66 20,14 +1,92% 2,41% 11.329
09/11/2017 19,94 19,94 19,65 19,76 +0,05% 1,45% 4.433
08/11/2017 19,95 20,12 19,75 19,75 -0,95% 1,85% 5.435
07/11/2017 20,25 20,25 19,77 19,94 -0,15% 2,37% 9.798
06/11/2017 20,20 20,25 19,84 19,97 +0,50% 2,03% 7.059
03/11/2017 19,70 19,98 19,70 19,87 +0,51% 1,42% 4.386
02/11/2017 19,93 20,15 19,61 19,77 -1,00% 2,71% 14.293
01/11/2017 20,00 20,00 19,55 19,97 +0,76% 2,25% 5.712
31/10/2017 20,15 20,24 19,26 19,82 -1,34% 4,86% 8.392
30/10/2017 20,15 20,19 19,88 20,09 +0,55% 1,54% 11.399
27/10/2017 20,07 20,40 19,00 19,98 -1,14% 6,98% 20.829